Iressa
IRESSA
Transforming the first-line treatment of EGFR mutation-positive advanced NSCLC
Read More
-
IRESSA (gefitinib) as a first-line treatment for EGFR mutation-positive advanced NSCLC
IRESSA is an oral monotherapy treatment which offers superior progression-free survival, better tolerability and quality of life compared with doublet chemotherapy (carboplatin/paclitaxel) as first-line treatment for EGFR mutation-positive advanced NSCLC.
Read More
-
The IPASS study
IPASS (IRESSA Pan-ASia Study) was an open label, randomised, parallel-group study that assessed the efficacy, safety and tolerability of IRESSA versus doublet chemotherapy (carboplatin/paclitaxel) as 1st line treatment in a clinically selected population of patients from Asia.
Read More
-
Identifying EGFR mutation positive patients
Epidermal growth factor receptor (EGFR) is a protein found in abnormally high levels on the surface of many types of cancer cells, particularly non-small cell lung cancer (NSCLC) cells. A patient‘s EGFR mutation status (positive or negative) can be confirmed via a diagnostic test using a sample of tumour tissue.
Read More
In Europe, IRESSA (gefitinib) is indicated for the treatment of adults with locally advanced or metastatic NSCLC (non small cell lung treatment) with activating mutations of EGFR-TK across all lines of therapy. For the latest IRESSA country by country indication information, please view here.
